(NASDAQ: IMUX) Immunic's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.51%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.
Immunic's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast IMUX's revenue for 2026 to be $63,049,005,669, with the lowest IMUX revenue forecast at $63,049,005,669, and the highest IMUX revenue forecast at $63,049,005,669. On average, 3 Wall Street analysts forecast IMUX's revenue for 2027 to be $34,454,593,067, with the lowest IMUX revenue forecast at $270,237,048, and the highest IMUX revenue forecast at $94,959,497,087.
In 2028, IMUX is forecast to generate $71,996,554,328 in revenue, with the lowest revenue forecast at $17,187,076,253 and the highest revenue forecast at $128,000,480,156.